We are happy to welcome the Canadian start-up Cellview to the Group. Specialized in innovative diagnostic via retinal imaging, it reinforces our med-tech strategy, enhancing early diagnosis of retinal pathologies and advancing vision health. Read more: essilorluxottica.com/en/newsroom/pr…

In 2024, EssilorLuxottica delivered another year of sound business expansion, with revenue growth at constant exchange rates of 6.0%.​ Read more: bit.ly/3CE7JAm

We are proud to announce the renewal of our successful collaboration with global icon Roger Federer for the design, manufacture, and worldwide distribution of eyewear under the RF and Oliver Peoples brands.​ Read more: bit.ly/3DUQwTT

We are proud to announce that our employee shareholding plans have reached a record level of investment, reflecting the strong confidence our people have in our strategy. Read more: bit.ly/41ZbQAN

In the first quarter, we successfully maintained strong momentum, with all regions and businesses contributing to steady growth – each playing an integral role in advancing our journey in the wearables and med-tech space. Read more: bit.ly/42L3Gv5

Our Annual Shareholders’ Meeting was held today in Paris. Shareholders approved all 17 resolutions. We thank all our shareholders for their trust and support during a time of profound transformation for our Group.​ Read more: bit.ly/4izds9f

Our EssilorLuxottica’s Excellence Laboratory in France was inaugurated this morning by President Emmanuel Macron. This state-of-the-art industrial facility embodies our unique know-how and ambitions to develop and transform our industry. Read more: bit.ly/4dekJdL

In 2025 we celebrate 35 years of operations in Japan through our "Made in Japan" campaign, a journey that promotes local talent, celebrate Japan's exceptional craftmanship in eyewear and highlights our enduring bond. Discover more here: bit.ly/3H7a3RX

We are pleased to announce today we have entered into an agreement with MidEuropa for EssilorLuxottica to acquire Optegra, a fast-growing and highly integrated eye hospital group.​ Read more: bit.ly/3ZCWDng

We are pleased to announce today that we have signed an agreement for the acquisition of one of the largest optical companies in Malaysia operating over 90 stores under the A-Look, Seen and OWL banners.​ Read more: bit.ly/4jwvZDH

Together with Meta, we are are proud to launch #OakleyMeta, a new category of Performance AI glasses for athletes and fans alike. Read more: bit.ly/44eXqfT

We are pleased to announce we have signed an agreement with the South Korean company PUcore for the acquisition of all its assets and entities involved in the development, manufacturing and sale of ophthalmic lens materials. ​Read more: bit.ly/4kNdOKs

With a strong first half of 2025, marked by top-line growth and momentum across all regions and businesses, we are keeping pace with our growth targets despite a volatile environment. Read more: bit.ly/3U29XOT

We are pleased to announce the acquisition of Automation & Robotics (A&R), a renowned player in the design and manufacture of automated systems for optical lens quality control. Read more: bit.ly/40QCBGC

Together with Meta Platforms, Inc., we showcased the evolution of our partnership at Meta Connect by unveiling the next generation of AI glasses, a breakthrough that reveals the next horizon in innovation, born from our deep collaboration. Read more: bit.ly/3IvvNYX

We are thrilled to have been granted FDA’s market authorization for Essilor Stellest in the U.S., bringing it to young patients in need of a solution to slow down myopia progression. Read more: bit.ly/4pIzH1c

We are proud to announce today that we have successfully completed the acquisition of Optegra, a fast-growing and highly integrated ophthalmology platform. Read more: bit.ly/46LGUF7

On #WorldSightDay, we are renewing our commitment to #TheRightToSee. Since 2013, through OneSight EssilorLuxottica Foundation, we have enabled access to vision care for over 1 billion people. Together, we are making clear vision a reality for all. Learn more: bit.ly/4pT1UTc

We are pleased to announce the acquisition of Ikerian AG, a health technology company, operating under the Retinai brand, specializing in AI and data management in eyecare.​ Read more: bit.ly/475pS51

We are pleased to announce today that our consolidated revenue for the third quarter of 2025 reached Euro 6,867 million, representing our strongest quarterly performance since the creation of the Group. Read more: bit.ly/47cBhQA